NandroMix-300 NPP,ND-DECA Blend Oil Steroids Injectable 300mg/ml

Description

DECA Nandrolone Decanoate 19-nor Injectable Research

Mechanism Overview

The pharmacology of NandroMix is defined by its 19-nor structural configuration, which results in a high anabolic-to-androgenic ratio compared to native testosterone. NandroMix activates nuclear androgen receptors (AR) to initiate the translocation of the receptor complex into the cell nucleus, triggering myogenic gene transcription. Nandrolone signaling promotes collagen biosynthesis within the fibroblast, facilitating studies on connective tissue repair. 19-nor molecules inhibit glucocorticoid receptor activity, effectively suppressing catabolic pathways in skeletal muscle cells. Binding kinetics indicate that NandroMix exhibits a binding affinity for the AR approximately 2.4 times higher than that of testosterone. Unlike testosterone, nandrolone converts to dihydronandrolone (DHN) via 5α-reductase, a metabolite with significantly lower androgenic activity. Quantitatively, the terminal half-life follows a bimodal curve, with peaks at 3 days (Phenylpropionate) and 15 days (Decanoate) (±1.5 days).

Product Profile

NandroMix is a sophisticated parenteral AAS formulation engineered to provide a synergistic pharmacokinetic profile by combining rapid-acting and long-acting esters of the 19-nortestosterone molecule. This multi-ester matrix utilizes the immediate receptor saturation provided by Nandrolone Phenylpropionate (NPP) alongside the protracted release kinetics of Nandrolone Decanoate (DECA). Researchers prioritize this compound for investigating chronic tissue remodeling and the modulation of joint synovial fluid in complex biological environments. By bypassing initial metabolic barriers, this oil-based delivery system ensures high bioavailability and stable plasma concentrations.

Product Specifications

• Primary Components: Nandrolone Phenylpropionate, Nandrolone Decanoate
• CAS Number: 360-70-3 (Decanoate) / 62-90-8 (Phenylpropionate)
• Molecular Formula: C28H44O3 / C27H34O3
• Purity: >99% confirmed via HPLC-UV and GC/MS
• Appearance: Clear, pale golden to amber viscous lipid solution
• Solubility: Optimized in organic carrier lipids including Grapeseed Oil and Ethyl Oleate

Research Observations

• Accelerated Tissue Accrual: Experimental data suggests significant increases in lean body mass over extended 12-to-16-week research phases.
• Synovial Homeostasis: Based on community feedback, effects include a marked reduction in joint discomfort due to enhanced fluid retention in synovial tissues.
• Erythropoietic Modulation: Published research indicates a dose-dependent increase in red blood cell count, improving oxygen delivery to peripheral tissues.
• Nitrogen Retention: Observed effects include a profound shift in positive nitrogen balance, protecting muscle tissue during metabolic stressors.
• Metabolic Optimization: Research models show improved nutrient partitioning, often co-administered with BPC 157 for synergistic recovery.

Key Points:
NandroMix remains a high-precision research tool for studying 19-nor mediated anabolic signaling and connective tissue homeostasis with a uniquely balanced pharmacokinetic profile.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.